SCHEMBL246984

SCHEMBL246984

COc1cc(-c2cnc(N3CCOCC3)cc2N)ccn1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.52
ATR Q13535 2/20 0.51
ATRIP Q8WXE1 1/20 0.51
LRRK2 Q5S007 5/20 0.44
GRM5 P41594 1/20 0.44
MAP4K1 Q92918 2/20 0.42
MTOR P42345 3/20 0.41
PIK3CA P42336 2/20 0.41
AKT1 P31749 1/20 0.41
PDE10A Q9Y233 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
EGLN1 Q9GZT9 2/20 0.41
PIK3CD O00329 1/20 0.41
FYN P06241 1/20 0.41
SMG1 Q96Q15 1/20 0.40
ALK Q9UM73 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246131 0.85 CYP2C19 (0.59) CYP2C19LRRK2MTORPIK3CAPDE10A
SCHEMBL246130 0.85 LRRK2 (0.50) CYP2C19ATRLRRK2MAP4K1MTOR
SCHEMBL246958 0.80 ALK (0.49) LRRK2MAP4K1MTORPIK3CAAKT1
SCHEMBL248166 0.78 ATR (0.49) CYP2C19ATRATRIPLRRK2MTOR
SCHEMBL248634 0.77 FYN (0.48) LRRK2MAP4K1MTORPIK3CAPDE10A
SCHEMBL247209 0.75 LRRK2 (0.43) CYP2C19LRRK2MTORPIK3CA
SCHEMBL16094363 0.74 LRRK2 (0.53) CYP2C19LRRK2MAP4K1MTORRAF1
SCHEMBL5564075 0.74 CYP2C19 (0.54) CYP2C19MAP4K1MTORPIK3CAAKT1
SCHEMBL247986 0.73 DYRK1A (0.45) ATR
SCHEMBL3410821 0.73 CNR2 (0.49) FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 CYP2C19 1555/4885ATR 203/4885ATRIP 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.